α-Methyldopa (α-MD) was administered intraperitoneally into adult male mice and its effect on α1- and α2-noradrenergic receptor binding sites in the brain was investigated, using [3H]WB-4101 and [3H]clonidine, respectively. A single injection of 50–200 mg/kg α-MD abolished the high affinity binding to α2-receptor sites and only the low affinity binding was observed with lower Bmax values. A significant effect of α-MD on α1-receptor sites was not detected even after repeated injections (200 mg/kg/day × 3). Pretreatment with fusaric acid or diethyldithiocarbamate (inhibitors of dopamine-β-hydroxylase) exerted no influence on the actions of α-MD on α2-receptor sites, whereas NSD-1055 (an inhibitor of dopa decarboxylase) inhibited the effects of α-MD. It is concluded, therefore, that α-methyldopamine, a decarboxylated metabolite of α-MD, may be responsible for the reducing effect of α-MD on α2-receptor sites.

Keywords:
α-Methyldopa, α-Noradrenergic binding sites, [3H]WB-4101, [3H]clonidine, Mouse brain
This content is only available via PDF.
© 1984 S. Karger AG, Basel
1984
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.